RAC media coverage, page-1880

Yes I am fully aware of the short attention span these days. Race has probably the most complex story of any ASX biotech in the number of different aspects you need to know to understand what we are doing - I continue to be surprised that we have any shareholders at all given this hurdle.

One area people could help is with suggestions of single standalone question that I could answer in 1 minute videos. I have a few already, but I am sure there are many more.

Examples.

”If bisantrene is such a great drug why was it not commercialised in the 1980s?”
“Why does chemotherapy damage the heart and why does it matter?”
”How can using two cancer killing drugs protect the heart from damage?”
”Why do large pharma companies look for in small biotechs?”
”How do large pharma companies value a drug they buy?”
”What causes small biotechs the most problems when selling a drug?”
”How can reformulation be worth so much?”